3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
2
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Blood Protein Disorders
1
Interventions
fludarabine phosphate
38
Peripheral Blood Stem Cell Transplantation
35
Whole-Body Irradiation
30
Mycophenolic Acid
29
Cyclophosphamide
27
Tacrolimus
21
Cyclosporine
20
Busulfan
17
Antilymphocyte Serum
14
Methotrexate
13
Melphalan
12
Sirolimus
9
Radiotherapy
8
Filgrastim
8
Etoposide
8
Cyclosporins
8
Cord Blood Stem Cell Transplantation
6
Transplantation
5
Methylprednisolone
5
Bortezomib
5
sargramostim
4
Therapeutics
4
Everolimus
4
Epoetin Alfa
4
Cytarabine
4
Carboplatin
4
thymoglobulin
3
fludarabine
3
Thiotepa
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
CLR1404
×
Plasma cell
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled